You are here
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
Real Time Oxygen Monitoring for Tissue Health Peripheral Artery Disease ApplicationSBC: PROFUSA, INC. Topic: NHLBI
DESCRIPTION provided by applicant Continuous biochemical monitoring has the power to change currently accepted standards of care shifting the emphasis from treating illness to maintaining health Point in time snapshots of a patientandapos s health can miss critical fluctuations or early warning signs that might warrant early interventions or changes in disease treatment and management PROFUS ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
Recyclable Magnetic Co C Hybrid ROMP Reagents Scavengers and LigandsSBC: MATERIA, INC. Topic: 300
DESCRIPTION provided by applicant This Fast Track Small Business Technology Transfer study between Materia Inc in Pasadena CA and the University of Kansas intends to build upon successes of our current Phase II Fast Track STTR grant R GM which ends on March Preliminary results serve as a solid foundation for this Fast Track submission entitled andquot Development of Re ...STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
Single Cell Analysis via Nanoscale Tip Enhanced Laser Ablation Mass SpectrometrySBC: Anasys Instruments Corp. Topic: NIGMS
DESCRIPTION provided by applicant The goal of the proposed Phase II STTR research is to develop an imaging system capable of detecting and identifying biomolecules in cells and tissue sections with sub cellular spatial resolution The system combines an atomic force microscope AFM with mass spectrometry MS analysis and utilizes a unique tip enhanced laser ablation TELA method developed in ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
Skin Sympathetic Nerve Activity and Cardiac ArrhythmiasSBC: ARRHYTHMOTECH Topic: NIDA
DESCRIPTION provided by applicant The objective of this Phase II STTR grant application is to continue the R Randamp D efforts initiated in Phase I The long term objective for Arrhythmotech is to develop and market an instrument for the simultaneous recording of sympathetic nerve activity SNA and electrocardiogram ECG using electrodes on the skin This method neuECG was discovered in Dr ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
Targeted Nanoparticles of Bismuth Organo Complexes for Spectral CT Imaging of CorSBC: Ocean Nanotech LLC Topic: NHLBI
DESCRIPTION provided by applicant Chest pain in patients presenting to the emergency department ED present a clinical dilemma transfer for emergent coronary revascularization admit overnight for cardiac telemetry and stress testing or discharge home with medical follow up In this proposal we hypothesize that a novel thrombus specific Spectral Computed Tomography Multicolored CT nanopar ...STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
Transdermal Naltrexone for Opiate Addiction and AlcoholismSBC: ALLTRANZ, INC. Topic: NIDA
DESCRIPTION (provided by applicant): According to the National Survey of Drug Use and Health (NSDUH) of 2008, 7.2 million Americans are in need of treatment for Substance-Related Disorders (SRDs), and a large proportion of those need treatment for opiate pain reliever, heroin, and alcohol addiction. Naltrexone (NTX), an opioid antagonist, is currently used in oral tablet form to help maintain opio ...STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
Urocortin Gene Transfer for CHF a Paracrine Approach Using Intravenous AAVSBC: Renova Therapeutics, Inc. Topic: NHLBI
DESCRIPTION provided by applicant Gene transfer for the treatment of cardiovascular diseases is bedeviled by inability to obtain safely and easily sufficient cardiac transgene expression Current methods of gene transfer for heart disease include intramuscular injection into heart muscle or intracoronary delivery approaches that are cumbersome to apply Consequently we have considered the u ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health